Although many surveillance methods (e.g., CEA, CT, and PET) have been used in clinical practice, 30−50% of CRC patients experience cancer recurrence and die from their cancer, indicating that there is an urgent need for new markers for detecting CRC recurrence. Here, CEACAM5 is linked to colorectal carcinoma.